China Medical System Holdings (CMS; HKG: 0867) announced that its subsidiary Rxilient Medical Pte. Ltd has entered into a licensing, collaboration, and supply agreement with Hefei Tianmai Biotechnology Co. Ltd regarding its second-generation insulin and third-generation insulin analogue insulin glargine.
Under the agreement, CMS will hold exclusive licensing rights to the drugs in Southeast Asia, covering regulatory filing, marketing, sales, and distribution. The license term spans ten years from the effective date to the first commercialization of the insulin product in the region. After this period, the agreement may be automatically renewed every three years based on specific conditions outlined in the contract. Financial terms were not disclosed.
Global Development Strategy
CMS has initiated its global development strategy, making significant progress in Southeast Asia. The company plans to create an open platform integrating innovative research, production, customized R&D and manufacturing (CDMO), sales, and promotion. It aims to collaborate with biotech and pharma companies from the US, Europe, Japan, and China to develop products.-Fineline Info & Tech
